Table 1. Patient characteristics and... | American Society of Hematology

Table 1.

Patient characteristics and clinical status

Study no.	Age, y	Sex	Diagnosis	Site of malignancy at enrollment	Prior therapy	Baseline NKT cell level, × 10⁶/L
KS101	53	F	Breast cancer	Bones, liver, lung	S,R,H	1.3
KS102	61	M	Colon cancer	Colon, retroperitoneum	S,R,C	0.15
KS103	27	F	Liver cancer	Liver, lungs	S	13.3
KS104	64	M	Melanoma	Subcutaneous, liver	S, I	0.50
KS202	64	M	Melanoma	Lungs	S	1.72
KS203	39	M	Peritoneal adenocarcinoma	Peritoneum	S	1.54
KS204	57	M	Renal cell carcinoma	Lungs, kidney, liver	S, R	12.79
KS205	51	M	Peritoneal adenocarcinoma	Peritoneum	I	1.23
KS301	65	M	Prostate carcinoma, plus renal cell carcinoma	Prostate, bones, lymph nodes, kidney	H, S	0.7
KS302	33	M	Lung adenocarcinoma	Lungs, mediastinum, bones	C	0.8
KS303	49	M	Renal cell carcinoma	Lungs, mediastinum, adrenal gland	S	1.17
KS304	47	F	Lung adenocarcinoma	Lungs, mediastinum, bones, liver	C	1.14

Study no.	Age, y	Sex	Diagnosis	Site of malignancy at enrollment	Prior therapy	Baseline NKT cell level, × 10⁶/L
KS101	53	F	Breast cancer	Bones, liver, lung	S,R,H	1.3
KS102	61	M	Colon cancer	Colon, retroperitoneum	S,R,C	0.15
KS103	27	F	Liver cancer	Liver, lungs	S	13.3
KS104	64	M	Melanoma	Subcutaneous, liver	S, I	0.50
KS202	64	M	Melanoma	Lungs	S	1.72
KS203	39	M	Peritoneal adenocarcinoma	Peritoneum	S	1.54
KS204	57	M	Renal cell carcinoma	Lungs, kidney, liver	S, R	12.79
KS205	51	M	Peritoneal adenocarcinoma	Peritoneum	I	1.23
KS301	65	M	Prostate carcinoma, plus renal cell carcinoma	Prostate, bones, lymph nodes, kidney	H, S	0.7
KS302	33	M	Lung adenocarcinoma	Lungs, mediastinum, bones	C	0.8
KS303	49	M	Renal cell carcinoma	Lungs, mediastinum, adrenal gland	S	1.17
KS304	47	F	Lung adenocarcinoma	Lungs, mediastinum, bones, liver	C	1.14

S indicates surgery; R, radiotherapy; H, hormonal antineoplastic therapy; C, chemotherapy; and I, immunotherapy.